Plasma viral loads following SHIV_SF162P3 vaginal challenge of 2G12-treated and control macaques.

<p>A total of nine female Indian rhesus macaques were divided into treatment groups of five animals for <i>i.v.</i> administration of 2G12, two animals to receive the isotype control (Dengue anti-NS1, DEN3), and two additional controls were challenged prior to the beginning of the protection study to confirm viral fitness, but were not treated with antibody. In (A) two 2G12-treated (40 mg/kg) animals became infected: 90154 reached peak viremia of 2×10⁷ on day 21 similar to controls; 95113 showed a one-week delay of infection onset and peak viremia was lower at 5×10⁶. The remaining three 2G12-treated animals were protected against infection and showed no measurable viremia. In (B) all 4 control animals experienced peak viremia between 1×10⁷ and 4×10⁷ on day 21. The quantity of SIV viral RNA genomic copy equivalents (vRNA copy Eq/ml) in EDTA-anticoagulated plasma was determined using quantitative RT PCR <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1000433#ppat.1000433-Friedrich1" target="_blank">[52]</a>. The assay minimum detection is 150 copies of vRNA Eq/ml (2.1 log) with a 99% confidence level.